Skip to main content

Table 1 Immunization and challenge treatment groups

From: Recombinant tandem epitope vaccination provides cross protection against Actinobacillus pleuropneumoniae challenge in mice

Group Group name Number of animals Immunization Dose Challenge
1 PBSC1 6 PBS 100 μg/0.2 mL/per mouse APP1
2 PBSC5 6 PBS 100 μg/0.2 mL/per mouse APP5b
3 RTAC1 6 RTA 0.2 mL/per mouse APP1
4 RTAC5 6 RTA 0.2 mL/per mouse APP5b
5 IB1-C1 6 inactivated APP1 108 CFU of APP1/0.2 mL/per mouse APP1
6 IB1-C5 6 inactivated APP1 108 CFU of APP1/0.2 mL/per mouse APP5b
7 IB5-C1 6 inactivated APP5b 108 CFU of APP5b/0.2 mL/per mouse APP1
8 IB5-C5 6 inactivated APP5b 108 CFU of APP5b/0.2 mL/per mouse APP5b
9 RTAIB1 + C1 6 RTA +inactivated APP1 100 μg of RTA + 108 CFU of APP1/0.2 mL/per mouse APP1
10 RTAIB1 + C5 6 RTA +inactivated APP1 100 μg of RTA + 108 CFU of APP1/0.2 mL/per mouse APP5b
11 RTAIB5 + C1 6 RTA +inactivated APP5b 100 μg of RTA + 108 CFU of APP5b/0.2 mL/per mouse APP1
12 RTAIB5 + C5 6 RTA +inactivated APP5b 100 μg of RTA + 108 CFU of APP5b/0.2 mL/per mouse APP5b
  1. Scheme parameters: first detected the level of antibody; recorded the clinical symptoms and the weight changes of mice; 72 h after infection: dissected the mice and weighed the lungs to calculate the lung index; measured the number of T cells of lung by flow cytometry; measure the cytokine level in serum and BALF of the RTA immunization group